Avidity Biosciences, Inc. (RNA)
Automate Your Wheel Strategy on RNA
With Tiblio's Option Bot, you can configure your own wheel strategy including RNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RNA
- Rev/Share 0.1513
- Book/Share 13.679
- PB 5.3315
- Debt/Equity 0.0265
- CurrentRatio 11.573
- ROIC -0.3112
- MktCap 10994197500.0
- FreeCF/Share -4.3181
- PFCF -18.4641
- PE -18.292
- Debt/Assets 0.0234
- DivYield 0
- ROE -0.377
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RNA | Roth Capital | -- | Buy | -- | $62 | Sept. 17, 2025 |
| Resumed | RNA | Goldman | -- | Buy | -- | $55 | July 10, 2025 |
| Initiation | RNA | Bernstein | -- | Outperform | -- | $50 | June 24, 2025 |
| Initiation | RNA | Wolfe Research | -- | Outperform | -- | $55 | June 17, 2025 |
| Initiation | RNA | Raymond James | -- | Strong Buy | -- | $65 | June 11, 2025 |
| Initiation | RNA | Citigroup | -- | Buy | -- | $70 | March 13, 2025 |
| Initiation | RNA | BMO Capital Markets | -- | Outperform | -- | $72 | March 12, 2025 |
| Initiation | RNA | Scotiabank | -- | Sector Outperform | -- | $70 | March 7, 2025 |
| Initiation | RNA | H.C. Wainwright | -- | Buy | -- | $72 | Dec. 20, 2024 |
| Initiation | RNA | Goldman | -- | Buy | -- | $59 | Sept. 24, 2024 |
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,000 shares of its common stock and 53,500 restricted stock units ("RSUs") to twenty-two (22) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees …
Read More
About Avidity Biosciences, Inc. (RNA)
- IPO Date 2020-06-12
- Website https://www.aviditybiosciences.com
- Industry Biotechnology
- CEO Sarah Boyce
- Employees 391